| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |